Alterations in Monocyte CD16 in Association with Diabetes Complications

Abstract EN

Monocytes express many cell surface markers indicative of their inflammatory and activation status.

Whether these markers are affected by diabetes and its complications is not known and was investigated in this study.

Blood was obtained from 22 nondiabetic and 43 diabetic subjects with a duration of diabetes >10 years, including 25 without and 18 with clinically significant complications.

The number of CD45+CD14+ monocytes and the percentage expressing the proinflammatory marker CD16 were determined by flow cytometry.

Other markers of monocyte activation and expression of chemokine receptors were also examined.

The relationship between monocyte CD16 and clinical data, selected cytokines, and chemokines was also investigated.

Diabetes had no effect on total white cell number but increased monocyte number.

Diabetes also significantly decreased the number of CD16+ monocytes but only in those with diabetic complications.

Other markers of monocyte activation status and chemokine receptors were not affected by diabetes or complications status.

Diabetes induced plasma proinflammatory cytokines and they were lower in diabetic subjects with complications compared to those without complications.

These results suggest that the circulating monocyte phenotype is altered by diabetic complications status.

These changes may be causally related to and could potentially be used to predict susceptibility to diabetic complications.